Paterson, Ross W. http://orcid.org/0000-0001-9372-3635
Gabelle, Audrey
Lucey, Brendan P.
Barthélemy, Nicolas R.
Leckey, Claire A.
Hirtz, Christophe
Lehmann, Sylvain
Sato, Chihiro http://orcid.org/0000-0002-7639-8727
Patterson, Bruce W.
West, Tim http://orcid.org/0000-0003-3267-8249
Yarasheski, Kevin
Rohrer, Jonathan D.
Wildburger, Norelle C. http://orcid.org/0000-0002-0036-8927
Schott, Jonathan M. http://orcid.org/0000-0003-2059-024X
Karch, Celeste M. http://orcid.org/0000-0002-6854-5547
Wray, Selina
Miller, Timothy M.
Elbert, Donald L.
Zetterberg, Henrik
Fox, Nick C.
Bateman, Randall J.
Article History
Accepted: 15 May 2019
First Online: 20 June 2019
Competing interests
: H.Z. declares that he has served on scientific advisory boards for Roche Diagnostics, Samumed, CogRx and Wave and is one of the founders of Brain Biomarker Solutions in Gothenburg, which is funded by GU Ventures (a Swedish government-owned company managed by the University of Gothenburg); these activities are all unrelated to this article. R.J.B. declares that he, along with Washington University, has an equity ownership interest in C<sub>2</sub>N Diagnostics (a mass-spectrometry-based biotechnology company that holds patents on the stable isotope labelling kinetics (SILK) technique in the United States and other countries) and receives royalties related to SILK and blood plasma assay technologies licensed by Washington University to C<sub>2</sub>N Diagnostics. R.J.B. declares that he receives income from C<sub>2</sub>N Diagnostics for serving on its scientific advisory board. B.W.P. declares that he receives consultancy fees from C<sub>2</sub>N Diagnostics. T.M. and R.J.B. have licensed superoxide dismutase 1 SILK to C<sub>2</sub>N Diagnostics. N.C.W. holds a patent for SILK studies utilizing nanoscale secondary ion mass spectroscopy. K.Y. and T.W. declare that they are employed by C<sub>2</sub>N Diagnostics. The other authors declare no competing interests.